Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Archives of Psychiatry and Clinical Neuroscience
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience 6/2006

01.09.2006 | ORIGINAL PAPER

Risperidone augmentation of clozapine

A critical review

verfasst von: Vassilis P. Kontaxakis, MD, PhD, Panayotis P. Ferentinos, MD, Beata J. Havaki-Kontaxaki, MD, PhD, Konstantinos G. Paplos, MD, Dimitra A. Pappa, MD, George N. Christodoulou, MD, FICPM, FRCPsych

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

Objective

Atypical antipsychotics are frequently used as augmentation agents in clozapine-resistant schizophrenic patients. Risperidone (RIS) is the one most studied as a clozapine (CLZ) adjunct. The aim of this study is to critically review all published studies regarding the efficacy and safety of RIS as an adjunctive agent in CLZ-resistant schizophrenic or schizoaffective patients.

Methods

A MEDLINE search from January 1988 to June 2005 was conducted. Identified papers were examined against several clinical, pharmacological and methodological parameters.

Results

A total of 15 studies were found (2 randomized controlled trials, 3 open-label trials (OTs) and 8 case-studies (CSs)) comprising 86 schizophrenic or schizoaffective patients (mean age 38.4 years). Mean CLZ dosage during the combined treatment was 474.2 mg/day. Plasma CLZ levels were assessed in 62 patients (72.1%). RIS was added at a mean dosage of 4.6 mg/day for a mean of 7.9 weeks. Significant improvement in psychopathology was reported for 37 patients (43%). A lower RIS dosage and a longer duration of the trial seemed to be associated with a better outcome. Main side effects reported were: extrapyramidal symptoms or akathisia (9.3%), sedation (7%) and hypersalivation (5.8%).

Conclusions

Existing evidence encourages the use of RIS as an adjunctive agent in CLZ-resistant schizophrenic or schizoaffective patients.
Literatur
1.
Adesanya A, Pantelis C (2000) Adjunctive risperidone treatment in patients with ‘clozapine-resistant schizophrenia’. Aust NZ J Psychiatry 34:533–534CrossRef
2.
Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, Ertugrul A, Jayathilake K, Gogus A, Tunca Z, Meltzer HY (2005) A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 66:63–72PubMedCrossRef
3.
Beauchemin MA, Millaud F, Nguyen KA (2002) A case of neuroleptic malignant syndrome with clozapine and risperidone. Can J Psychiatry 47:886PubMed
4.
Breier A, Buchanan RW, Irish D, Carpenter WT Jr (1993) Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry 44:1145–1149PubMed
5.
Buckley P, Miller A, Olsen J, Garver D, Miller DD, Csernansky J (2001) When symptoms persist: clozapine augmentation strategies. Schizophr Bull 27:615–628PubMed
6.
Byerly MJ, DeVane CL (1996) Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 16:177–187PubMedCrossRef
7.
Chong SA, Remington G (2000) Clozapine augmentation: safety and efficacy. Schizophr Bull 26:421–440PubMed
8.
Chong SA, Tan CH, Lee HS (1996) Hoarding and clozapine–risperidone combination. Can J Psychiatry 41:315–316PubMed
9.
Chong SA, Tan CH, Lee HS (1997) Atrial ectopics with clozapine–risperidone combination. J Clin Psychopharmacol 17:130–131PubMedCrossRef
10.
Conley RR, Kelly DL (2001) Management of treatment resistance in schizophrenia. Biol Psychiatry 50:898–911PubMedCrossRef
11.
De Groot IW, Heck AH, van Harten PN (2001) Addition of risperidone to clozapine therapy in chronically psychotic inpatients. J Clin Psychiatry 62:129–130PubMedCrossRef
12.
Freudenreich O, Goff DC (2002) Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 106:323–330PubMedCrossRef
13.
Godleski LS, Sernyak MJ (1996) Agranulocytosis after addition of risperidone to clozapine treatment. Am J Psychiatry 153:735–736PubMed
14.
Henderson DC, Goff DC (1996) Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 57:395–397PubMed
15.
Henderson DC, Goff DC, Connolly CE, Borba CP, Hayden D (2001) Risperidone added to clozapine: impact on serum prolactin levels. J Clin Psychiatry 62:605–608PubMedCrossRef
16.
Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, Shaughnessy RA (2005) Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 162:130–136PubMedCrossRef
17.
Kane J, Honigfeld G, Singer J, Meltzer H, the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796PubMed
18.
Kapur S, Zipursky RB, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286–293PubMed
19.
Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Paplos KG, Roukas DK, Christodoulou GN (2005) Case studies of adjunctive agents in clozapine-resistant schizophrenic patients. Clin Neuropharmacol 28:50–53PubMedCrossRef
20.
Kontaxakis VP, Havaki-Kontaxaki BJ, Stamouli SS, Christodoulou GN (2002) Toxic interaction between risperidone and clozapine: a case report. Prog Neuropsychopharmacol Biol Psychiatry 26:407–409PubMedCrossRef
21.
Koreen AR, Lieberman JA, Kronig M, Cooper TB (1995) Cross-tapering clozapine and risperidone. Am J Psychiatry 152:1690PubMed
22.
Llorca PM, Lancon C, Disdier B, Farisse J, Sapin C, Auquier P (2002) Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. J Psychiatry Neurosci 27:30–37PubMed
23.
Mauri MC, Volonteri LS, Dell’Osso B, Regispani F, Papa P, Baldi M, et al. (2003) Predictors of clinical outcome in schizophrenic patients responding to clozapine. J Clin Psychopharmacol 23:660–664PubMedCrossRef
24.
McCarthy RH, Terkelsen KG (1995) Risperidone augmentation of clozapine. Pharmacopsychiatry 28:61–63PubMedCrossRef
25.
Meltzer HY, Burnett S, Bastani B, Ramirez LF (1990) Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 41:892–897PubMed
26.
Morera AL, Barreiro P, Cano-Munoz JL (1999) Risperidone and clozapine combination for the treatment of refractory schizophrenia. Acta Psychiatr Scand 99:305–307PubMed
27.
Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227–235PubMedCrossRef
28.
Perry PJ, Miller DD, Arndt SV, Cadoret RJ (1991) Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148:231–235PubMed
29.
Procyshyn RM, Tse G, Sin O, Flynn S (2002) Concomitant clozapine reduces smoking in patients treated with risperidone. Eur Neuropsychopharmacol 12:77–80PubMedCrossRef
30.
Raaska K, Raitasuo V, Neuvonen PJ (2002) Therapeutic drug monitoring data: risperidone does not increase serum clozapine concentration. Eur J Clin Pharmacol 58:587–591PubMedCrossRef
31.
Raju GVL, Kumar R, Khanna S (2001) Clozapine–risperidone combination in treatment-resistant schizophrenia. Aust NZ J Psychiatry 35:543
32.
Raskin S, Katz G, Zislin Z, Knobler HY, Durst R (2000) Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiatr Scand 101:334–336PubMedCrossRef
33.
Senechal A, Landry P, Deschamps R, Lessard M (2002) Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs [Article in French]. Encephale 28:567–569PubMed
34.
Spina E, Scordo MG (2001) Newer antipsychotics: comparative review of drug interactions. Expert Rev Neurother 1:171–182CrossRefPubMed
35.
Stahl SM, Grady MM (2004) A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 11:313–327PubMedCrossRef
36.
Taylor CG, Flynn SW, Altman S, Ehmann T, MacEwan GW, Honer WG (2001) An open trial of risperidone augmentation of partial response to clozapine. Schizophr Res 48:155–158PubMedCrossRef
37.
Tyson SC, Devane CL, Risch SC (1995) Pharmacokinetic interaction between risperidone and clozapine. Am J Psychiatry 152:1401–1402PubMed
Metadaten
Titel
Risperidone augmentation of clozapine
A critical review
verfasst von
Vassilis P. Kontaxakis, MD, PhD
Panayotis P. Ferentinos, MD
Beata J. Havaki-Kontaxaki, MD, PhD
Konstantinos G. Paplos, MD
Dimitra A. Pappa, MD
George N. Christodoulou, MD, FICPM, FRCPsych
Publikationsdatum
01.09.2006
Erschienen in
European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 6/2006
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-006-0643-9

Weitere Artikel der Ausgabe 6/2006

European Archives of Psychiatry and Clinical Neuroscience 6/2006 Zur Ausgabe

ORIGINAL PAPER

Cognitive functioning in the early course of first-episode schizophrenia spectrum disorders

ORIGINAL PAPER

Cognitive predictors of skill acquisition on social problem solving in patients with schizophrenia

ORIGINAL PAPER

The quality of life of the mentally ill living in residential facilities

ORIGINAL PAPER

Father–infant interaction patterns as precursors of children’s later externalizing behavior problems

REVIEW

Evidence for beneficial effects of antidepressants on suicidality in depressive patients

ORIGINAL PAPER

Relationship between insight, cognitive function, social function and symptomatology in schizophrenia

Neu im Fachgebiet Psychiatrie

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise